Coinfection

Coinfection arises when a host is infected at the same time by multiple pathogens, including combinations of viruses, bacteria, fungi, or parasites. The supplied grounding does not support a more specific causal aetiology beyond the presence of concurrent infectious agents.

The biological effects of coinfection depend on the interacting pathogens and can be synergistic, antagonistic, or neutral with respect to replication and disease expression. Reviews describe pathogen-pathogen interactions, immune response modulation, and altered pathology as key mechanisms, with respiratory viral coinfections specifically noted to influence disease dynamics. Polymicrobial infections are also associated with more severe clinical outcomes and heightened antibiotic tolerance.

The grounding supports increased risk in settings where exposure to multiple pathogens is likely, but it does not provide a general list of patient-level risk factors for coinfection. For specific examples, severe viral infection can enable secondary invasion by other organisms, and tuberculosis patients with underlying comorbidities and lung damage are described as being prone to worse outcomes during COVID-19-related disruption. Endemic infectious disease settings and strained health systems are also mentioned in relation to higher burden and poorer outcomes.

There is no single standard treatment for coinfection in the supplied grounding because management depends on the pathogens involved. The abstracts support pathogen-specific treatment and diagnostic clarification, including accurate identification of multiple infectious agents to avoid misdiagnosis. For the specific example of COVID-19-associated pulmonary aspergillosis, first-line therapy is described at the drug-class level as azole antifungals, with liposomal amphotericin B considered when azole resistance is a concern.